Reasons for Hope in Metastatic Breast Cancer: A Clinical Context Report MedPage Today BANKHEAD: What about the class of drugs known as the mTOR inhibitors? There has also been a considerable amount of interest in those. ANDERS: Sure. So the class of mTOR inhibitors, particularly everolimus, has been very promising in metastatic breast ... |
